One-year access to more than 500 world journals available in the system
-
http://medilib.ir
- Duration of Time : 365 Day
Price : 300$- Special Price : 100$
At the Cusp — Reimagining Infective Endocarditis Care amid the Opioid Epidemic
Michael A. Incze, M.D., M.S.Ed.
doi : 10.1056/NEJMp2032066
N Engl J Med 2021; 384:297-299
Toward a Medical “Ecology of Attention”
Mark J. Kissler, M.D., Katherine Kissler, M.S., and Marisha Burden, M.D.
doi : 10.1056/NEJMp2027190
N Engl J Med 2021; 384:299-301
The Surgeon and the Mother
Heather Carmichael, M.D.
doi : 10.1056/NEJMp2029239
N Engl J Med 2021; 384:302-303
Cryoablation or Drug Therapy for Initial Treatment of Atrial Fibrillation
Jason G. Andrade, M.D., George A. Wells, Ph.D., Marc W. Deyell, M.D., Matthew Bennett, M.D., Vidal Essebag, M.D., Ph.D., Jean Champagne, M.D., Jean-Francois Roux, M.D., Derek Yung, M.D., Allan Skanes, M.D., Yaariv Khaykin, M.D., Carlos Morillo, M.D., Umjeet Jolly, M.D.,
doi : 10.1056/NEJMoa2029980
N Engl J Med 2021; 384:305-315
Guidelines recommend a trial of one or more antiarrhythmic drugs before catheter ablation is considered in patients with atrial fibrillation. However, first-line ablation may be more effective in maintaining sinus rhythm.
Cryoballoon Ablation as Initial Therapy for Atrial Fibrillation
Oussama M. Wazni, M.D., Gopi Dandamudi, M.D., Nitesh Sood, M.D., Robert Hoyt, M.D., Jaret Tyler, M.D., Sarfraz Durrani, M.D., Mark Niebauer, M.D., Kevin Makati, M.D., Blair Halperin, M.D., Andre Gauri, M.D., Gustavo Morales, M.D., Mingyuan Shao, Ph.D.,
doi : 10.1056/NEJMoa2029554
N Engl J Med 2021; 384:316-324
In patients with symptomatic paroxysmal atrial fibrillation that has not responded to medication, catheter ablation is more effective than antiarrhythmic drug therapy for maintaining sinus rhythm. However, the safety and efficacy of cryoballoon ablation as initial first-line therapy have not been established.
Inhaled Treprostinil in Pulmonary Hypertension Due to Interstitial Lung Disease
Aaron Waxman, M.D., Ph.D., Ricardo Restrepo-Jaramillo, M.D., Thenappan Thenappan, M.D., Ashwin Ravichandran, M.D., Peter Engel, M.D., Abubakr Bajwa, M.D., Roblee Allen, M.D., Jeremy Feldman, M.D., Rahul Argula, M.D., Peter Smith, Pharm.D., Kristan Rollins, Pharm.D., Chunqin Deng, M.D., Ph.D.,
doi : 10.1056/NEJMoa2008470
N Engl J Med 2021; 384:325-334
No therapies are currently approved for the treatment of pulmonary hypertension in patients with interstitial lung disease. The safety and efficacy of inhaled treprostinil for patients with this condition are unclear.
Levonorgestrel vs. Copper Intrauterine Devices for Emergency Contraception
David K. Turok, M.D., Alexandra Gero, M.P.H., Rebecca G. Simmons, Ph.D., Jennifer E. Kaiser, M.D., Gregory J. Stoddard, M.P.H., Corinne D. Sexsmith, M.S., Lori M. Gawron, M.D., and Jessica N. Sanders, Ph.D.
doi : 10.1056/NEJMoa2022141
N Engl J Med 2021; 384:335-344
In the United States, more intrauterine device (IUD) users select levonorgestrel IUDs than copper IUDs for long-term contraception. Currently, clinicians offer only copper IUDs for emergency contraception because data are lacking on the efficacy of the levonorgestrel IUD for this purpose.
Resumption of Cardiac Activity after Withdrawal of Life-Sustaining Measures
Sonny Dhanani, M.D., Laura Hornby, M.Sc., Amanda van Beinum, M.Sc., Nathan B. Scales, Ph.D., Melanie Hogue, M.Sc., Andrew Baker, M.D., Stephen Beed, M.D., J. Gordon Boyd, M.D., Ph.D., Jennifer A. Chandler, L.L.B., L.L.M., Michaël Chassé, M.D., Ph.D., Frederick D’Aragon, M.D., Ph.D., Cameron Dezfulian, M.D.,
doi : 10.1056/NEJMoa2022713
N Engl J Med 2021; 384:345-352
The minimum duration of pulselessness required before organ donation after circulatory determination of death has not been well studied.
Atrial Fibrillation
Gregory F. Michaud, M.D., and William G. Stevenson, M.D.
doi : 10.1056/NEJMcp2023658
N Engl J Med 2021; 384:353-361
Changing Hand Color after Carpal Tunnel Injection
David Burke, M.D.
doi : 10.1056/NEJMicm2005527
N Engl J Med 2021; 384:362
A Pulsating Leg
Moran S. Gal, M.D., and Shoshana Greenberger, M.D., Ph.D.
doi : 10.1056/NEJMicm2022429
N Engl J Med 2021; 384:e8
Case 3-2021: A 48-Year-Old Man with Transient Vision Loss
Sebastian H. Unizony, M.D., Hillary R. Kelly, M.D., Elizabeth K. O’Donnell, M.D., and Sam Sadigh, M.D.
doi : 10.1056/NEJMcpc2002416
N Engl J Med 2021; 384:363-372
Early Ablation for Paroxysmal Atrial Fibrillation — Safety First
Joseph E. Marine, M.D.
doi : 10.1056/NEJMe2033534
N Engl J Med 2021; 384:374-375
Optimism for Interstitial Lung Disease–Associated Pulmonary Hypertension?
Darren B. Taichman, M.D., Ph.D.
doi : 10.1056/NEJMe2033181
N Engl J Med 2021; 384:376-377
Audio Interview: A Covid-19 Conversation with Anthony Fauci
Eric J. Rubin, M.D., Ph.D., Lindsey R. Baden, M.D., Anthony S. Fauci, M.D., and Stephen Morrissey, Ph.D.
doi : 10.1056/NEJMe2101618
N Engl J Med 2021; 384:e22
Antigen Presentation by B Cells in Multiple Sclerosis
Scott S. Zamvil, M.D., Ph.D., and Stephen L. Hauser, M.D.
doi : 10.1056/NEJMcibr2032177
N Engl J Med 2021; 384:378-381
Effect of CD47 Blockade on Vascular Inflammation
doi : 10.1056/NEJMc2029834
N Engl J Med 2021; 384:382-383
Dapagliflozin in Patients with Chronic Kidney Disease
doi : 10.1056/NEJMc2032809
N Engl J Med 2021; 384:388-390
